Board members

About Epigeneron

Tetsuya Mishima


Tetsuya Mishima has served as the CEO of Epigeneron since March, 2021. Prior to joining Epigeneron, he was the CEO of Anaeropharma Science, a clinical stage biotech company. Prior to Anaeropharma, He was a partner of Watervein Partners, a venture capital firm, which he co-founded in 2002. Prior to founding Watervein, he was involved in the M&A advisory business at Bank of America Investment Banking, and in the pharmaceutical business at AGC. Throughout his career, he has extensive experiences in pharmaceutical development, alliance management, fundraising, and venture investment. He received a B.S. and an M.S. in Polymer Science at Tokyo Institute of Technology.

Hodaka Fujii, M.D., Ph.D.

Founder and Director, CSO

Dr. Hodaka Fujii is a Founder and the CSO of Epigeneron. He is also a Professor at Hirosaki University Graduate School of Medicine and School of Medicine. Prior to this position, he was an Associate Professor at Osaka University and an Assistant Professor at New York University School of Medicine, and a Scientific Member of Basel Institute for Immunology. During his professional career, Dr. Fujii has focused on immunology, molecular biology and epigenetics / chromatin. He received an M.D. and Ph.D. from the University of Tokyo School of Medicine and Graduate School of Medicine, respectively.

Masayuki Furutsuka

Director, Business Development

Mr. Masayuki Furutsuka has focused on alliance, collaboration and partnering through strategic and transformational transactions in pharmaceutical industry totaling over $5 Billion in value. Prior to joining Epigeneron in 2019, Mr. Furutsuka was Business Development and Partnering Head of Japan Vaccine business unit at Takeda. Prior to Takeda, he served as a head of Japan group, Corporate business development / Global business Development at Eisai where he led the corporate partnering initiatives. From 2000 to 2007, he was in research division and business development at Astellas. He holds an M.S. in the agriculture science at Kobe University.

Yasuhiro Imaeda, Ph.D.

Director, Head of R&D

Dr. Yasuhiro Imaeda was appointed as one of the board directors of Epigeneron in January, 2022. Before joining Epigeneron in August, 2021, he has been engaged in the drug discovery research for more than 25 years and worked as Director in Neuroscience and Oncology Drug Discovery Units at Takeda Pharmaceutical Company, and successfully created multiple drug candidates which entered clinical trials. He received European Federation for Medicinal Chemistry Best Poster Prize and Medicinal Chemistry Symposium Award for Excellent General Presentation. He received a Ph.D. in agriculture sciences from Kyoto University.

Atsushi Usami, Ph.D.


Dr. Atsushi Usami is a Partner and one of the Board Directors of The University of Tokyo Edge Capital Partners Co. Ltd. (UTEC). Since joining in 2013, he has focused on seed / early-stage life science investments. He currently serves on the board of Epigeneron Inc. Before joining UTEC, he worked as a strategy consultant at Mitsubishi Research Institute (MRI).  He received a Ph.D. in pharmaceutical sciences from the University of Tokyo and is a pharmacist.

Keisuke Ide


Mr. Keisuke Ide is a Partner at The University of Tokyo Edge Capital Partners Co. Ltd. (UTEC). He invests in deep tech early stage startups. He has many years of experience in startup investing, management consulting, and also engineering in semiconductor industry. He has a BS in systems engineering from the University of Virginia, and an MS degree in management science from Stanford University.